ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases

Baruch D. Kuppermann, Paul Bernstein, Jordi Mones, Diana V. Do, Ron Neumann, Philip J. Rosenfeld

Research output: Contribution to journalReview articlepeer-review


Topics change as time flows. This is especially true in retinal therapeutics that merely 25 years ago was mainly a surgical field and in two decades has been transformed into a classic pharmacologic medical field. That said, the classic questions of pharmacology such as pharmacokinetics, pharmacodynamics, dosing and delivery systems currently engage most retina specialists. It was therefore easy for us to focus the 2018 ISOPT Clinical retinal discussions on delivery systems, drug efficacy and classic questions such as: have we reached the unbreakable glass ceiling of efficacy in wet age-related macular degeneration (AMD)? Can we aim our target to achieve an even higher effect? Can it be reached by new chemical/biological entities or would delivery system allow us to reach higher points of efficacy? The discussion also addressed the issue of dry AMD and the glorious parade of failures so far, and how do we measure success and failure via relevant endpoints.

Original languageEnglish (US)
Pages (from-to)424-432
Number of pages9
JournalJournal of Ocular Pharmacology and Therapeutics
Issue number8
StatePublished - Oct 2019


  • AMD dry & wet
  • clinical trials
  • endpoints
  • retina
  • retinal imaging

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases'. Together they form a unique fingerprint.

Cite this